Dupixent Leads

Better Than Buying Dupixent Leads

Legal Calls sells exclusive Dupixent leads and signed retainers to law firms. Claimants allege Dupixent (dupilumab) caused or accelerated cutaneous T-cell lymphoma, including mycosis fungoides and Sezary syndrome. Leads come from our own Meta, TikTok and Google ads, are screened by our in-house intake team, and are delivered by CRM, API, email or warm transfer.

Dupixent Leads & Signed Retainers

Superior Performance, Superior Pricing

To get a Custom Quote Today

Dupixent Leads: Key Facts & Litigation Status

Dupixent Leads at a Glance

Case typePharmaceutical product liability (dupilumab)
LitigationMDL No. 3180, D.N.J., Judge Zahid N. Quraishi (created June 4, 2026)
Alleged injuriesCutaneous T-cell lymphoma: mycosis fungoides, Sezary syndrome
Lead sourcesMeta, TikTok & Google ads — no affiliates
What you getExclusive leads or signed retainers
DeliveryCRM, API, email or warm transfer
IntakeIn-house team, under 1-minute speed-to-lead
ProofTrustedForm certificate, call recordings, ad account access
VolumeOn request
Last reviewedNovember 2026

Dupixent Litigation Status

On June 4, 2026 the JPML created MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey before Judge Zahid N. Quraishi. About 15 actions were centralized at the start. Defendants include Regeneron Pharmaceuticals and Sanofi-Aventis U.S. LLC.

The Panel did not decide whether T-cell lymphomas other than CTCL belong in the MDL. The FDA listed Dupixent and CTCL as a potential signal of serious risk in its adverse event reporting system report for October-December 2024, published in 2025. The Dupixent label does not carry a lymphoma warning.

As of November 2026 the MDL is at an early stage. The initial case management conference was held October 1, 2026, plaintiffs’ leadership was appointed in October, and a November 2, 2026 order set phased discovery starting with general causation, running into 2028. About 40 actions were pending as of early November 2026. No bellwether schedule or settlement had been reported.

Sources: Dupixent MDL Created in New Jersey (Weitz & Luxenberg) · JPML Centralizes Actions Alleging Link Between Dupixent, T-Cell Lymphoma (HarrisMartin) · Dupixent Lawsuit (King Law) · Dupixent Lawsuit News: MDL 3180 Docket Updates (Marin Murphy). Status as of November 2026.

What Sets Us Apart From Other Dupixent Lead Vendors?

Years of Excellence
14 +
Ad Spend Managed
78 M+
Leads Delivered
390 k+

Real Customers, Real Satisfaction

Dupixent Client Acquisition Example Criteria & Pricing

Criteria shown is generalized based on current standards in this mass tort. Tailored criteria sets are available to meet client specifications.

To get a Custom Quote Today

How It Works & Pricing

How Our Dupixent Campaigns Work

  1. We run our own Meta, TikTok and Google ads aimed at Dupixent users later diagnosed with T-cell lymphoma.
  2. Pre-screen questions confirm Dupixent use, the CTCL diagnosis and that it followed the start of treatment.
  3. Our in-house intake team calls within a minute to verify the biopsy, prior history and available records.
  4. Qualified claimants are delivered to your firm by CRM, API, email or warm transfer, or as signed retainers.

Leads or Signed Retainers — Your Choice

Exclusive Dupixent leads: pre-screened claimants delivered in real time to your CRM, by API, by email or as a warm transfer, for your own team to sign.

Signed Dupixent retainers: our in-house intake team qualifies the claimant and collects the signed retainer and HIPAA authorization before the case is delivered.

Pricing: a percentage of ad spend, or a fixed price per signed retainer. Volume is available on request.

More about Our Dupixent Client Acquisition Signed Retainers

Dupixent Leads: Frequently Asked Questions

Is there an MDL for Dupixent?

Yes. MDL No. 3180 was created on June 4, 2026 in the District of New Jersey before Judge Zahid N. Quraishi.

What injuries qualify?

Cutaneous T-cell lymphoma, including mycosis fungoides and Sezary syndrome, diagnosed after Dupixent use began. Whether other T-cell lymphomas belong in the MDL has not been decided.

Does a history of eczema disqualify a claimant?

No. Eczema is the main reason people take Dupixent. Intake instead screens out lymphoma diagnosed before Dupixent was started.

Are your Dupixent leads exclusive?

Yes. Each lead is sold to one firm only and comes from our own ads, not affiliates, with a TrustedForm certificate and call recording.

Do you sell signed Dupixent retainers?

Yes. Firms can buy exclusive leads or signed retainers, priced as a percentage of ad spend or a fixed price per signed retainer.

How far along is the Dupixent litigation?

Early. As of November 2026 the MDL had appointed plaintiffs’ leadership and set phased discovery starting with general causation, with no bellwether schedule or settlement.

Related Mass Tort Leads

Keytruda Leads · Ozempic Leads · Oxbryta Leads · Mass Tort Intake · All mass tort case leads

Are You Price-Shopping for Dupixent Leads?

Prices are always changing and tend to rise over time. We work with you to get the lowest client acquisition cost in the industry by tailoring our service to your needs.

Book a time with our VP, and he’ll walk you through pricing and strategy step by step.